Skip to main content

Advertisement

SpringerLink
Log in

The role of LAT1 in 18F-DOPA uptake in malignant gliomas

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Positron emission tomography (PET) imaging with the amino acid tracer 6-18F-fluoro-l-3,4-dihydroxy-phenylalanine (18F-DOPA) may provide better spatial and functional information in human gliomas than CT or MRI alone. The l-type amino acid transporter 1 (LAT1) is responsible for membrane transport of large neutral amino acids in normal cells. This study assessed the relationship between LAT1 expression and 18F-DOPA uptake in human astrocytomas. Endogenous LAT1 expression was measured in established glioblastoma (GBM) cell lines and primary GBM xenografts using Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR). Uptake of 18F-DOPA was approximated in vitro using 3H-l-DOPA as an analog. Uptake of 3H-l-DOPA was assessed in cells expressing LAT1 shRNA or LAT1 siRNA and compared to non-targeted (NT) control shRNA or siRNA sequences, respectively. To demonstrate the clinical relevance of these findings, LAT1 immunofluorescence staining was compared with corresponding regions of 18F-DOPA PET uptake in patients with newly diagnosed astrocytomas. LAT1 mRNA and protein expression varies in GBM, and the extent of 3H-l-DOPA uptake was positively correlated with endogenous LAT1 expression. Stable shRNA-mediated LAT1 knockdown in T98 and GBM28 reduced 3H-l-DOPA uptake relative to NT shRNA by 57 (P < 0.0001) and 52 % (P < 0.001), respectively. Transient siRNA-mediated LAT1 knockdown in T98 reduced 3H-l-DOPA uptake relative to NT siRNA up to 68 % (P < 0.01). In clinical samples, LAT1 expression positively correlated with 18F-DOPA PET uptake (P = 0.04). Expression of LAT1 is strongly associated with 3H-l-DOPA uptake in vitro and 18F-DOPA uptake in patient biopsy samples. These results define LAT1 as a key determinant of 18F-DOPA accumulation in GBM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W (2009) 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 71:242–248. doi:10.1016/j.ejrad.2008.04.018

    Article  PubMed  Google Scholar 

  2. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911

    PubMed  CAS  Google Scholar 

  3. Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A (2009) Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 34:878–883. doi:10.1097/RLU.0b013e3181becfe0

    Article  PubMed  Google Scholar 

  4. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J (2012) Impact of 3,4-dihydroxy-6-18F-fluoro-l-phenylalanine PET/CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med 53:393–398. doi:10.2967/jnumed.111.095711

    Article  PubMed  CAS  Google Scholar 

  5. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC (2007) 18F-FDOPA kinetics in brain tumors. J Nucl Med 48:1651–1661. doi:10.2967/jnumed.106.039321

    Article  PubMed  Google Scholar 

  6. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S (2000) The 4F2hc/LAT1 complex transports l-DOPA across the blood-brain barrier. Brain Res 879:115–121

    Article  PubMed  CAS  Google Scholar 

  7. del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of l-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161–174. doi:10.1016/j.ejps.2008.06.015

    Article  PubMed  Google Scholar 

  8. Pinho MJ, Serrao MP, Gomes P, Hopfer U, Jose PA, Soares-da-Silva P (2004) Over-expression of renal LAT1 and LAT2 and enhanced l-DOPA uptake in SHR immortalized renal proximal tubular cells. Kidney Int 66:216–226. doi:10.1111/j.1523-1755.2004.00722.x

    Article  PubMed  CAS  Google Scholar 

  9. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629–23632

    Article  PubMed  CAS  Google Scholar 

  10. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T (2010) Correlation of l-methyl-11C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas. J Neurooncol 99:217–225. doi:10.1007/s11060-010-0117-9

    Article  PubMed  CAS  Google Scholar 

  11. Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y, Nagane M (2008) Enhanced tumor growth elicited by l-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery 62:493–503. doi:10.1227/01.neu.0000316018.51292.19 discussion 503–494

    Article  PubMed  Google Scholar 

  12. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H (2006) l-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119:484–492. doi:10.1002/ijc.21866

    Article  PubMed  CAS  Google Scholar 

  13. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164–176. doi:10.1215/S1152851704000821

    Article  PubMed  CAS  Google Scholar 

  14. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11:281–291. doi:10.1215/15228517-2008-090

    Article  PubMed  CAS  Google Scholar 

  15. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23:1409–1415

    Article  PubMed  CAS  Google Scholar 

  16. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T (2008) 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009–2017. doi:10.1007/s00259-008-0847-5

    Article  PubMed  CAS  Google Scholar 

  17. Pafundi DH, Brinkmann DH, Parney IF, Giannini C, Laack NN, Kemp B, Lowe V, Sarkaria JN, Yan ES (2011) Biopsy validation of (18)F-FDOPA-PET uptake and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: preliminary results of a prospective pilot study. Int J Radiat Oncol 81:S182–S182

    Article  Google Scholar 

  18. Asano S, Kameyama M, Oura A, Morisato A, Sakai H, Tabuchi Y, Chairoungdua A, Endou H, Kanai Y (2007) l-type amino acid transporter-1 expressed in human astrocytomas, U343MGa. Biol Pharm Bull 30:415–422

    Article  PubMed  CAS  Google Scholar 

  19. Soares-da-Silva P, Serrao MP (2004) High- and low-affinity transport of l-leucine and l-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells. Am J Physiol Renal Physiol 287:F252–F261. doi:10.1152/ajprenal.00030.2004

    Article  PubMed  CAS  Google Scholar 

  20. Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmoller J (2009) Influx and efflux transport as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 78:45–53. doi:10.1016/j.bcp.2009.03.026

    Article  PubMed  Google Scholar 

  21. Kim CH, Park KJ, Park JR, Kanai Y, Endou H, Park JC, Kim do K (2006) The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res 26:2943–2948

    PubMed  CAS  Google Scholar 

  22. Kumakura Y, Vernaleken I, Grunder G, Bartenstein P, Gjedde A, Cumming P (2005) PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. J Cereb Blood Flow Metab 25:807–819. doi:10.1038/sj.jcbfm.9600079

    Article  PubMed  CAS  Google Scholar 

  23. Bauer R, Brust P, Walter B, Vorwieger G, Bergmann R, Fuchtner F, Steinbach J, el-Hallag E, Fritz A, Johannsen B, Zwiener U (2000) Relation between brain tissue pO2 and dopamine synthesis of basal ganglia—a 18FDOPA-PET study in newborn piglets. J Perinat Med 28:54–60. doi:10.1515/JPM.2000.008

    Article  PubMed  CAS  Google Scholar 

  24. Beuthien-Baumann B, Bredow J, Burchert W, Fuchtner F, Bergmann R, Alheit HD, Reiss G, Hliscs R, Steinmeier R, Franke WG, Johannsen B, Kotzerke J (2003) 3-O-methyl-6-[18F]fluoro-l-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging 30:1004–1008. doi:10.1007/s00259-003-1205-2

    Article  PubMed  CAS  Google Scholar 

  25. Lennernas H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK (1993) The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol 35:243–250

    Article  PubMed  CAS  Google Scholar 

  26. Morimoto E, Kanai Y, Kim do K, Chairoungdua A, Choi HW, Wempe MF, Anzai N, Endou H (2008) Establishment and characterization of mammalian cell lines stably expressing human l-type amino acid transporters. J Pharmacol Sci 108:505–516

    Article  PubMed  CAS  Google Scholar 

  27. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I (2011) High expression of l-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 61:281–289. doi:10.1111/j.1440-1827.2011.02650.x

    Article  PubMed  CAS  Google Scholar 

  28. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M (2009) l-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 99:433–438. doi:10.1002/jso.21277

    Article  PubMed  Google Scholar 

  29. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K (2010) Comparison of l-type amino acid transporter 1 expression and l-[3-18F]-alpha-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol 37:911–916. doi:10.1016/j.nucmedbio.2010.06.004

    Article  PubMed  CAS  Google Scholar 

  30. Kobayashi H, Ishii Y, Takayama T (2005) Expression of l-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90:233–238. doi:10.1002/jso.20257

    Article  PubMed  CAS  Google Scholar 

  31. Nakanishi K, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Mukai M, Ikeda E, Ozeki Y, Aida S, Kawai T (2006) LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch 448:142–150. doi:10.1007/s00428-005-0063-7

    Article  PubMed  CAS  Google Scholar 

  32. Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Kawai T (2007) Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451:681–690. doi:10.1007/s00428-007-0457-9

    Article  PubMed  CAS  Google Scholar 

  33. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I (2009) l-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59:7–18. doi:10.1111/j.1440-1827.2008.02319.x

    Article  PubMed  CAS  Google Scholar 

  34. Ebara T, Kaira K, Saito J, Shioya M, Asao T, Takahashi T, Sakurai H, Kanai Y, Kuwano H, Nakano T (2010) l-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer. Anticancer Res 30:4223–4227

    PubMed  CAS  Google Scholar 

  35. Boado RJ, Li JY, Tsukamoto H, Pardridge WM (2003) Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem 85:1037–1042

    Article  PubMed  CAS  Google Scholar 

  36. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N (2011) LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 3:468–478

    PubMed  CAS  Google Scholar 

  37. Cohen A, Hall MN (2009) An amino acid shuffle activates mTORC1. Cell 136:399–400. doi:10.1016/j.cell.2009.01.021

    Article  PubMed  CAS  Google Scholar 

  38. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J (2011) Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 71:7525–7536. doi:10.1158/0008-5472.CAN-11-1821

    Article  PubMed  CAS  Google Scholar 

  39. Roos S, Kanai Y, Prasad PD, Powell TL, Jansson T (2009) Regulation of placental amino acid transporter activity by mammalian target of rapamycin. Am J Physiol Cell Physiol 296:C142–C150. doi:10.1152/ajpcell.00330.2008

    Article  PubMed  CAS  Google Scholar 

  40. Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, Kim do K (2008) BCH, an inhibitor of system l amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31:1096–1100

    Article  PubMed  CAS  Google Scholar 

  41. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M, Kanai Y (2010) Inhibition of l-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 30:4819–4828

    PubMed  CAS  Google Scholar 

  42. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H (2010) l-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101:173–179. doi:10.1111/j.1349-7006.2009.01386.x

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Funding provided by Brains Together for a Cure and by the Mayo Brain Tumor NIH SPORE Grant (CA108961).

Author information

Authors and Affiliations

  1. College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Ryan S. Youland & Judi A. Ramiscal

  2. Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Gaspar J. Kitange, Deanna H. Pafundi, Jenny L. Pokorny, Nadia N. Laack, Debra H. Brinkmann & Jann N. Sarkaria

  3. Department of Neurosurgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Timothy E. Peterson & Ian F. Parney

  4. Department of Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Caterina Giannini

  5. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Val J. Lowe

Authors
  1. Ryan S. Youland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaspar J. Kitange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy E. Peterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deanna H. Pafundi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Judi A. Ramiscal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jenny L. Pokorny
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caterina Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nadia N. Laack
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ian F. Parney
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Val J. Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Debra H. Brinkmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jann N. Sarkaria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jann N. Sarkaria.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Youland, R.S., Kitange, G.J., Peterson, T.E. et al. The role of LAT1 in 18F-DOPA uptake in malignant gliomas. J Neurooncol 111, 11–18 (2013). https://doi.org/10.1007/s11060-012-0986-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0986-1

Keywords

Search

Navigation